{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-058956","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.649685+00:00","generated_at":"2026-05-23T05:16:19.728035+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"confidence":"high","headline":"CG Oncology reports 42.3% 24-month CR rate in BOND-003; 97.3% progression-free at 24 mo","bullets":["BOND-003 Cohort C: 75.5% complete response (CR) at any time; 42.3% 24-month CR by K-M estimate.","Median duration of response 28 months; 58.3% of responders maintained CR at 24 months by K-M.","97.3% of patients free from progression to muscle-invasive bladder cancer at 24 months; 91.6% cystectomy-free.","No Grade 3+ treatment-related adverse events or deaths; median resolution of any TRAE was one day.","Cohort P (Ta/T1 without CIS): 90.5% high-grade recurrence-free survival at 3 and 9 months (n=24)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-058956","json":"https://secwatch.observer/filing/0000950170-25-058956.json","markdown":"https://secwatch.observer/filing/0000950170-25-058956.md","text":"https://secwatch.observer/filing/0000950170-25-058956.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000095017025058956/0000950170-25-058956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000095017025058956/ck0001991792-20250426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:16:19.728035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}